Generali Asset Management SPA SGR Boosts Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Generali Asset Management SPA SGR raised its stake in Thermo Fisher by 25.7% in Q4 to 21,047 shares, worth about $12.20 million.
• Thermo Fisher beat quarterly expectations with $5.44 EPS on $11.01 billion revenue and set FY2026 guidance of 24.640–25.120 EPS, while analysts maintain a consensus "Buy" with a $623.05 target.
• Insiders sold 5,800 shares (≈$2.96 million) in the last three months—including sales by the COO and CEO—while institutional investors hold roughly 89.2% of the stock.

Generali Asset Management SPA SGR lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 25.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,047 shares of the medical research company's stock after buying an additional 4,307 shares during the period. Generali Asset Management SPA SGR's holdings in Thermo Fisher Scientific were worth $12,196,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of TMO. JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth about $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $29,000. Olistico Wealth LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $29,000. Cloud Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth about $31,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new position in Thermo Fisher Scientific during the third quarter worth about $38,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $473.58 on Friday. The company's 50 day simple moving average is $493.53 and its 200-day simple moving average is $546.70. The company has a market capitalization of $175.99 billion, a price-to-earnings ratio of 26.04, a price-to-earnings-growth ratio of 2.09 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business's revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were paid a $0.47 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date of this dividend was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 10.34%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wells Fargo & Company set a $683.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Barclays reduced their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 14th. DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They set a "buy" rating and a $610.00 target price on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Finally, Stifel Nicolaus reduced their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating on the stock in a research note on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $623.05.

Insider Buying and Selling

In other news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company's stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company's stock, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,800 shares of company stock worth $2,963,544 over the last three months. Insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.